News|Articles|August 5, 2025
Daily Derm Times: August 4, 2025
Listen
0:00 / 0:00
Key Takeaways
- Amlitelimab enhances clinical outcomes and quality of life in atopic dermatitis, indicating potential for long-term disease control.
- EVERESSE monopolar RF technology improves patient care with increased safety, comfort, and effective skin rejuvenation.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Advertisement
To stay up-to-date with the latest dermatology news, sign up to receive our
Amlitelimab Improves QoL and Disease Control in AD
Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.
How EVERESSE Monopolar RF is Revolutionizing Patient Care, According to Dendy Engelman, MD, FACMS, FAAD
Dendy Engelman, MD, FACMS, FAAD, explores the benefits of EVERESSE monopolar RF technology, emphasizing safety, comfort, and effective skin rejuvenation.
Molecular Insights Into ICI-Induced Skin Toxicities
Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) show distinct immune profiles from classic skin conditions.
Vidutolimod Combo Therapy Shows Promise in Treating Advanced Melanoma
New clinical trial results reveal that intratumoral vidutolimod combined with pembrolizumab shows promise for treating advanced melanoma resistant to PD-1 therapy.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
